Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
NCT00003136
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of amifostine, carboplatin and cyclophosphamide, followed by peripheral stem cell transplantation, in treating patients with epithelial ovarian cancer or primary peritone... Read More
Gender:
FEMALE
Ages:
65 years and below
Trial Updated:
02/08/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
NCT00268905
Completed
The purpose of this study is to determine the maximum tolerated dose (MTD) and to explore the safety and anti-tumor activity of E7389 in combination with carboplatin in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2013
Locations: Not set, New Brunswick, New Jersey +10 locations
Conditions: Cancer
Register for Updates
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
NCT00287937
Completed
This phase I trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with advanced or refractory solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat toge... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2013
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00027898
Completed
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of combining bortezomib with carboplatin and etoposide in treating patients who have advanced solid tumors that have not responded to previous treatment
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/06/2013
Locations: University of Colorado, Denver, Colorado
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim
NCT00280787
Completed
Patients enrolled on this study will have been diagnosed with non-small cell lung cancer which cannot be removed by an operation. The standard treatment for this disease is a combination of chemotherapy and radiation therapy; however, the best way to combine these treatments is not known. This study will examine if the combination of chemotherapy and radiotherapy has an increased effect on slowing tumor growth with the addition of a drug called ZD1839. In this study, chemotherapy will be given... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2013
Locations: University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Non Small Cell Lung Cancer
Register for Updates
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00004934
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving paclitaxel and carboplatin with epirubicin is more effective than paclitaxel and carboplatin alone for ovarian epithelial, fallopian tube, or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and carboplatin with or without epirubicin in treating patients who have stage IIB, stage III, or sta... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/01/2013
Locations: St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota +17 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
NCT00008203
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Biological therapy may interfere with the growth of the cancer cells. It is not yet known which post-transplant biological therapy regimen is more effective for breast cancer. PURPOSE: Randomi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
02/01/2013
Locations: Herbert Irving Comprehensive Cancer Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
NCT00042835
Terminated
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib and radiation therapy with combination chemotherapy may kill more tumor cells. Phase I trial to study the effectiveness of combining erlotinib and radiation therapy with combination chemotherapy in treatin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2013
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00004011
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +286 locations
Conditions: Lung Cancer
Register for Updates
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
NCT00055835
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy before radiation therapy, and combining chemotherapy with radiation therapy, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of neoadjuvant gemcitabine, paclitaxel, and carboplatin followed by cispl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +91 locations
Conditions: Bladder Cancer, Urethral Cancer
Register for Updates
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
NCT00305942
Completed
This proposed phase II trial will investigate the combination of topotecan/carboplatin in the first-line treatment of patients with extensive-stage SCLC. Topotecan/platinum regimens are emerging as common treatments for patients with extensive-stage disease. This trial will be one of the first clinical trials to evaluate a combination of weekly topotecan and carboplatin in the first-line treatment of extensive-stage SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2013
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +15 locations
Conditions: Carcinoma, Small Cell
Register for Updates
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00086944
Completed
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Register for Updates